NZ587312A - Combination of alpha 7 nicotinic agonists and antipsychotics - Google Patents

Info

Publication number

NZ587312A

NZ587312A NZ587312A NZ58731209A NZ587312A NZ 587312 A NZ587312 A NZ 587312A NZ 587312 A NZ587312 A NZ 587312A NZ 58731209 A NZ58731209 A NZ 58731209A NZ 587312 A NZ587312 A NZ 587312A

Authority

NZ

New Zealand

Prior art keywords

pyridinyl

azabicyclo

oct

methyl

carboxamide

Prior art date

2008-02-13

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000181 nicotinic agonist Substances 0.000 title claims abstract description 79
• 239000000164 antipsychotic agent Substances 0.000 title claims abstract description 40
• 229940005529 antipsychotics Drugs 0.000 title description 12
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 152
• 238000011282 treatment Methods 0.000 claims abstract description 63
• 208000020016 psychiatric disease Diseases 0.000 claims abstract description 41
• 230000006735 deficit Effects 0.000 claims abstract description 38
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
• 208000028017 Psychotic disease Diseases 0.000 claims abstract description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
• 230000006870 function Effects 0.000 claims abstract description 20
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 15
• 230000002195 synergetic effect Effects 0.000 claims abstract description 14
• 230000002265 prevention Effects 0.000 claims abstract description 13
• 208000026139 Memory disease Diseases 0.000 claims abstract description 12
• 230000010365 information processing Effects 0.000 claims abstract description 6
• 150000001875 compounds Chemical class 0.000 claims description 80
• 239000003814 drug Substances 0.000 claims description 64
• 150000003839 salts Chemical class 0.000 claims description 64
• 239000012453 solvate Substances 0.000 claims description 54
• 230000000561 anti-psychotic effect Effects 0.000 claims description 50
• -1 cycloalkyi Chemical group 0.000 claims description 48
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 43
• 229960004170 clozapine Drugs 0.000 claims description 42
• 229960004431 quetiapine Drugs 0.000 claims description 35
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 35
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 33
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
• 239000001301 oxygen Substances 0.000 claims description 33
• 229910052760 oxygen Inorganic materials 0.000 claims description 33
• 125000003118 aryl group Chemical group 0.000 claims description 31
• 239000003693 atypical antipsychotic agent Substances 0.000 claims description 28
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
• 229940127236 atypical antipsychotics Drugs 0.000 claims description 25
• 125000000623 heterocyclic group Chemical group 0.000 claims description 24
• 125000003107 substituted aryl group Chemical group 0.000 claims description 22
• 125000000217 alkyl group Chemical group 0.000 claims description 21
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 16
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 15
• OXKRFEWMSWPKKV-GHTZIAJQSA-N n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide Chemical compound C([C@@H]1N2CCC(CC2)[C@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-GHTZIAJQSA-N 0.000 claims description 15
• 239000004202 carbamide Substances 0.000 claims description 14
• 125000001188 haloalkyl group Chemical group 0.000 claims description 14
• 229910052736 halogen Inorganic materials 0.000 claims description 14
• 150000002367 halogens Chemical class 0.000 claims description 14
• 239000002207 metabolite Substances 0.000 claims description 14
• 229910052757 nitrogen Inorganic materials 0.000 claims description 14
• 125000003342 alkenyl group Chemical group 0.000 claims description 13
• 150000003857 carboxamides Chemical class 0.000 claims description 11
• NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 11
• 229960002419 flupentixol Drugs 0.000 claims description 11
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 10
• 125000001072 heteroaryl group Chemical group 0.000 claims description 10
• 229960005017 olanzapine Drugs 0.000 claims description 10
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 10
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
• 239000001257 hydrogen Substances 0.000 claims description 8
• 229910052739 hydrogen Inorganic materials 0.000 claims description 8
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
• 238000002360 preparation method Methods 0.000 claims description 8
• 229910052717 sulfur Chemical group 0.000 claims description 8
• 239000011593 sulfur Chemical group 0.000 claims description 8
• VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims description 7
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 7
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 7
• CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims description 7
• 229960003036 amisulpride Drugs 0.000 claims description 7
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 7
• 229960004372 aripiprazole Drugs 0.000 claims description 7
• 229960005245 asenapine Drugs 0.000 claims description 7
• 125000004429 atom Chemical group 0.000 claims description 7
• 229950009087 bifeprunox Drugs 0.000 claims description 7
• 125000005842 heteroatom Chemical group 0.000 claims description 7
• 229960001057 paliperidone Drugs 0.000 claims description 7
• 229960001534 risperidone Drugs 0.000 claims description 7
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 7
• 229960000652 sertindole Drugs 0.000 claims description 7
• GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 7
• 229960000607 ziprasidone Drugs 0.000 claims description 7
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 7
• 229960004496 zotepine Drugs 0.000 claims description 7
• HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 7
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
• 229960001076 chlorpromazine Drugs 0.000 claims description 5
• 229960003878 haloperidol Drugs 0.000 claims description 5
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• 229960000762 perphenazine Drugs 0.000 claims description 5
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
• 239000011976 maleic acid Substances 0.000 claims description 4
• STUXELCGSPOOKH-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1SC2=CC=CC=C2C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 STUXELCGSPOOKH-UHFFFAOYSA-N 0.000 claims description 3
• DKQONJLFEFAATJ-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound ClC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 DKQONJLFEFAATJ-UHFFFAOYSA-N 0.000 claims description 3
• LCZJSGLDIXDUBV-UHFFFAOYSA-N 1-(2-cyanophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC=C(C#N)C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 LCZJSGLDIXDUBV-UHFFFAOYSA-N 0.000 claims description 3
• POIZEQOOLWQOTB-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound COC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 POIZEQOOLWQOTB-UHFFFAOYSA-N 0.000 claims description 3
• YOADJMCDQNIXFJ-UHFFFAOYSA-N 1-(2-methylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound CC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 YOADJMCDQNIXFJ-UHFFFAOYSA-N 0.000 claims description 3
• BOEXHAMRFZNHQT-UHFFFAOYSA-N 1-(2-methylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound CSC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 BOEXHAMRFZNHQT-UHFFFAOYSA-N 0.000 claims description 3
• VKLKUACEXUCPLW-UHFFFAOYSA-N 1-(2-phenoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC=C(OC=2C=CC=CC=2)C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 VKLKUACEXUCPLW-UHFFFAOYSA-N 0.000 claims description 3
• ITOSOOOIIWHHFB-UHFFFAOYSA-N 1-(2-phenylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC=C(SC=2C=CC=CC=2)C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 ITOSOOOIIWHHFB-UHFFFAOYSA-N 0.000 claims description 3
• SDTJVIDGLJAXKM-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 SDTJVIDGLJAXKM-UHFFFAOYSA-N 0.000 claims description 3
• WDCXLHAUHFGKOF-UHFFFAOYSA-N 1-(3-bromophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound BrC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 WDCXLHAUHFGKOF-UHFFFAOYSA-N 0.000 claims description 3
• HKAXJWRSTUXFSC-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound ClC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 HKAXJWRSTUXFSC-UHFFFAOYSA-N 0.000 claims description 3
• KQQPQAIVTLTOJA-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC(C#N)=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 KQQPQAIVTLTOJA-UHFFFAOYSA-N 0.000 claims description 3
• SRERTUCRFYUTPW-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound FC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 SRERTUCRFYUTPW-UHFFFAOYSA-N 0.000 claims description 3
• XFKONSBVAKEWBP-UHFFFAOYSA-N 1-(3-methoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound COC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 XFKONSBVAKEWBP-UHFFFAOYSA-N 0.000 claims description 3
• BWXJPTIEYNPYIH-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 BWXJPTIEYNPYIH-UHFFFAOYSA-N 0.000 claims description 3
• SUQVRBOOIFBQOK-UHFFFAOYSA-N 1-(3-methylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound CSC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 SUQVRBOOIFBQOK-UHFFFAOYSA-N 0.000 claims description 3
• WFPBURVJRDQRPT-UHFFFAOYSA-N 1-(3-phenoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 WFPBURVJRDQRPT-UHFFFAOYSA-N 0.000 claims description 3
• JOBOTDLKSIRVKK-UHFFFAOYSA-N 1-(3-phenylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC(SC=2C=CC=CC=2)=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JOBOTDLKSIRVKK-UHFFFAOYSA-N 0.000 claims description 3
• ZWXIQEUZDPMEKN-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(Br)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 ZWXIQEUZDPMEKN-UHFFFAOYSA-N 0.000 claims description 3
• RVCABVIKWGPMAV-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 RVCABVIKWGPMAV-UHFFFAOYSA-N 0.000 claims description 3
• SLYKLRLIVBDQDW-UHFFFAOYSA-N 1-(4-cyanophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=C(C#N)C=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 SLYKLRLIVBDQDW-UHFFFAOYSA-N 0.000 claims description 3
• IQKKYLOHMCQPSX-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(F)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 IQKKYLOHMCQPSX-UHFFFAOYSA-N 0.000 claims description 3
• XOCXGISRYQTMMC-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 XOCXGISRYQTMMC-UHFFFAOYSA-N 0.000 claims description 3
• QAQZILRXQQXXHK-UHFFFAOYSA-N 1-(4-methylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(C)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 QAQZILRXQQXXHK-UHFFFAOYSA-N 0.000 claims description 3
• CJJKWWRNHSEIAI-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(SC)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 CJJKWWRNHSEIAI-UHFFFAOYSA-N 0.000 claims description 3
• UKEJLBZTQWWYAL-UHFFFAOYSA-N 1-(4-phenoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 UKEJLBZTQWWYAL-UHFFFAOYSA-N 0.000 claims description 3
• BWWBAJHMMQOSEN-UHFFFAOYSA-N 1-(4-phenylsulfanylphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=C(SC=2C=CC=CC=2)C=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 BWWBAJHMMQOSEN-UHFFFAOYSA-N 0.000 claims description 3
• NTAZIMVJXVIOMB-UHFFFAOYSA-N 1-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 NTAZIMVJXVIOMB-UHFFFAOYSA-N 0.000 claims description 3
• ZXNQLIISARYPIL-UHFFFAOYSA-N 1-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylurea Chemical compound C=1C=CSC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 ZXNQLIISARYPIL-UHFFFAOYSA-N 0.000 claims description 3
• DNVZONZLTWKXFU-UHFFFAOYSA-N 1-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylurea Chemical compound C1=CSC=C1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 DNVZONZLTWKXFU-UHFFFAOYSA-N 0.000 claims description 3
• PLBRJYVRNDEBQU-UHFFFAOYSA-N 1-[4-(dimethylamino)phenyl]-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 PLBRJYVRNDEBQU-UHFFFAOYSA-N 0.000 claims description 3
• ROASJKJYZJOLLX-UHFFFAOYSA-N 1-benzyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]indole-3-carboxamide Chemical compound C=1N(CC=2C=CC=CC=2)C2=CC=CC=C2C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 ROASJKJYZJOLLX-UHFFFAOYSA-N 0.000 claims description 3
• JBLCIQZBAQAMME-UHFFFAOYSA-N 1-naphthalen-1-yl-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JBLCIQZBAQAMME-UHFFFAOYSA-N 0.000 claims description 3
• UQMWOYQMOZMBJT-UHFFFAOYSA-N 1-naphthalen-2-yl-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 UQMWOYQMOZMBJT-UHFFFAOYSA-N 0.000 claims description 3
• ILLQWAWHZINEKF-UHFFFAOYSA-N 1-propan-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzotriazole-5-carboxamide Chemical compound C=1C=C2N(C(C)C)N=NC2=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 ILLQWAWHZINEKF-UHFFFAOYSA-N 0.000 claims description 3
• DRFVAKIYRQITRO-UHFFFAOYSA-N 2-benzylidene-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]butanamide Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2NC(=O)C(CC)=CC1=CC=CC=C1 DRFVAKIYRQITRO-UHFFFAOYSA-N 0.000 claims description 3
• HSALPTZHVKEDOV-UHFFFAOYSA-N 2-fluoro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound FC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 HSALPTZHVKEDOV-UHFFFAOYSA-N 0.000 claims description 3
• SNRGXXZKZKDAMT-UHFFFAOYSA-N 3-(3,4-dimethylthieno[2,3-b]thiophen-5-yl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound CC=1C=2C(C)=CSC=2SC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 SNRGXXZKZKDAMT-UHFFFAOYSA-N 0.000 claims description 3
• NMDRJVMUHHSXPO-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=C(O)C(OC)=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 NMDRJVMUHHSXPO-UHFFFAOYSA-N 0.000 claims description 3
• BMOWREPJSKPNTF-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(SC)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 BMOWREPJSKPNTF-UHFFFAOYSA-N 0.000 claims description 3
• HKOLPJJBJJIXTA-UHFFFAOYSA-N 3-(furan-3-yl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=COC=C1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HKOLPJJBJJIXTA-UHFFFAOYSA-N 0.000 claims description 3
• NPIGVSLSCILMQF-UHFFFAOYSA-N 3-chloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1Cl NPIGVSLSCILMQF-UHFFFAOYSA-N 0.000 claims description 3
• BLOYCIJJVGNWOB-UHFFFAOYSA-N 3-fluoro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound FC1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 BLOYCIJJVGNWOB-UHFFFAOYSA-N 0.000 claims description 3
• NLELYJFWWXULAE-UHFFFAOYSA-N 3-naphthalen-1-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=CC2=CC=CC=C2C=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 NLELYJFWWXULAE-UHFFFAOYSA-N 0.000 claims description 3
• NYVHBOPWELJGQF-UHFFFAOYSA-N 3-pyridin-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=CC=NC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 NYVHBOPWELJGQF-UHFFFAOYSA-N 0.000 claims description 3
• OQFNODATXJBYQO-UHFFFAOYSA-N 4-fluoro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 OQFNODATXJBYQO-UHFFFAOYSA-N 0.000 claims description 3
• CPVQPWNTKCICMZ-UHFFFAOYSA-N 5-acetyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)C)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 CPVQPWNTKCICMZ-UHFFFAOYSA-N 0.000 claims description 3
• GJXMTNBBRFVFSM-UHFFFAOYSA-N 5-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carbothioamide Chemical compound S1C(C)=CC=C1C(=S)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 GJXMTNBBRFVFSM-UHFFFAOYSA-N 0.000 claims description 3
• PIEZNFVNSICXLK-UHFFFAOYSA-N 5-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(C)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 PIEZNFVNSICXLK-UHFFFAOYSA-N 0.000 claims description 3
• YYJFQMZQEUBYBV-UHFFFAOYSA-N 5-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carbothioamide Chemical compound C=1C=C(C=2C=CC=CC=2)SC=1C(=S)NC1C(CC2)CCN2C1CC1=CC=CN=C1 YYJFQMZQEUBYBV-UHFFFAOYSA-N 0.000 claims description 3
• HMBGJHCWZLRYIN-UHFFFAOYSA-N 5-pyridin-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C=1C=C(C=2N=CC=CC=2)SC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HMBGJHCWZLRYIN-UHFFFAOYSA-N 0.000 claims description 3
• VSPORRWEMGMMDL-UHFFFAOYSA-N 6-amino-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-2-carboxamide Chemical compound C1=CC2=CC(N)=CC=C2C=C1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 VSPORRWEMGMMDL-UHFFFAOYSA-N 0.000 claims description 3
• 208000024254 Delusional disease Diseases 0.000 claims description 3
• 208000020186 Schizophreniform disease Diseases 0.000 claims description 3
• 208000019568 Shared Paranoid disease Diseases 0.000 claims description 3
• 208000028810 Shared psychotic disease Diseases 0.000 claims description 3
• VKLFERZVPLUITJ-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(1-benzothiophen-3-yl)carbamate Chemical compound C=1SC2=CC=CC=C2C=1NC(=O)OC1C(CC2)CCN2C1CC1=CC=CN=C1 VKLFERZVPLUITJ-UHFFFAOYSA-N 0.000 claims description 3
• ASRXVRDHQBUGDH-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-bromophenyl)carbamate Chemical compound BrC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 ASRXVRDHQBUGDH-UHFFFAOYSA-N 0.000 claims description 3
• SUFRYFIHXUXOSZ-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-chlorophenyl)carbamate Chemical compound ClC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 SUFRYFIHXUXOSZ-UHFFFAOYSA-N 0.000 claims description 3
• HHZIMFZJSRQNDD-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-cyanophenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC=C1C#N HHZIMFZJSRQNDD-UHFFFAOYSA-N 0.000 claims description 3
• DNPXKLXPQCETBM-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-fluorophenyl)carbamate Chemical compound FC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 DNPXKLXPQCETBM-UHFFFAOYSA-N 0.000 claims description 3
• OMJJDJNPADXBPJ-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-methoxyphenyl)carbamate Chemical compound COC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 OMJJDJNPADXBPJ-UHFFFAOYSA-N 0.000 claims description 3
• JIAGGXIAQWVHPB-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-methylphenyl)carbamate Chemical compound CC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 JIAGGXIAQWVHPB-UHFFFAOYSA-N 0.000 claims description 3
• FOAOIXLKWJTADM-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-methylsulfanylphenyl)carbamate Chemical compound CSC1=CC=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 FOAOIXLKWJTADM-UHFFFAOYSA-N 0.000 claims description 3
• TZSMWLPWLOMJMI-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-phenoxyphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 TZSMWLPWLOMJMI-UHFFFAOYSA-N 0.000 claims description 3
• LBULDYUSJUPTLD-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2-phenylsulfanylphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC=C1SC1=CC=CC=C1 LBULDYUSJUPTLD-UHFFFAOYSA-N 0.000 claims description 3
• IDOADSDJAGHRFX-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3,4-dichlorophenyl)carbamate Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 IDOADSDJAGHRFX-UHFFFAOYSA-N 0.000 claims description 3
• YIHFFZDIUIVOJC-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-bromophenyl)carbamate Chemical compound BrC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 YIHFFZDIUIVOJC-UHFFFAOYSA-N 0.000 claims description 3
• OIQWQXPAJPYTGT-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-chlorophenyl)carbamate Chemical compound ClC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 OIQWQXPAJPYTGT-UHFFFAOYSA-N 0.000 claims description 3
• WLVOAUDOALHRRO-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-cyanophenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC(C#N)=C1 WLVOAUDOALHRRO-UHFFFAOYSA-N 0.000 claims description 3
• HCABTHYWBCMRGU-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)carbamate Chemical compound FC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 HCABTHYWBCMRGU-UHFFFAOYSA-N 0.000 claims description 3
• WMXQCLBTPLTMMU-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-methoxyphenyl)carbamate Chemical compound COC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 WMXQCLBTPLTMMU-UHFFFAOYSA-N 0.000 claims description 3
• BQABCNAVPVVAIO-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-methylsulfanylphenyl)carbamate Chemical compound CSC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 BQABCNAVPVVAIO-UHFFFAOYSA-N 0.000 claims description 3
• SEKMNJOYFNUIME-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-phenoxyphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC(C=1)=CC=CC=1OC1=CC=CC=C1 SEKMNJOYFNUIME-UHFFFAOYSA-N 0.000 claims description 3
• DKILQHNULGGEDD-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-phenylsulfanylphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC(C=1)=CC=CC=1SC1=CC=CC=C1 DKILQHNULGGEDD-UHFFFAOYSA-N 0.000 claims description 3
• SWAPELXGNLSFEZ-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-bromophenyl)carbamate Chemical compound C1=CC(Br)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 SWAPELXGNLSFEZ-UHFFFAOYSA-N 0.000 claims description 3
• CHYCPJZIRYQRKU-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-cyanophenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=C(C#N)C=C1 CHYCPJZIRYQRKU-UHFFFAOYSA-N 0.000 claims description 3
• NJQPRLLGPWXPMV-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-fluorophenyl)carbamate Chemical compound C1=CC(F)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 NJQPRLLGPWXPMV-UHFFFAOYSA-N 0.000 claims description 3
• IPQDDDUPSPGGON-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-methoxyphenyl)carbamate Chemical compound C1=CC(OC)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 IPQDDDUPSPGGON-UHFFFAOYSA-N 0.000 claims description 3
• KSYFKNNOVPCSKN-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-methylphenyl)carbamate Chemical compound C1=CC(C)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 KSYFKNNOVPCSKN-UHFFFAOYSA-N 0.000 claims description 3
• YKRUZJDHAKZIBH-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-methylsulfanylphenyl)carbamate Chemical compound C1=CC(SC)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 YKRUZJDHAKZIBH-UHFFFAOYSA-N 0.000 claims description 3
• WQAMKZUPBNDBAR-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-phenoxyphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 WQAMKZUPBNDBAR-UHFFFAOYSA-N 0.000 claims description 3
• XBOHHLSXMQFYCZ-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-phenylsulfanylphenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC(C=C1)=CC=C1SC1=CC=CC=C1 XBOHHLSXMQFYCZ-UHFFFAOYSA-N 0.000 claims description 3
• NUHAWKIAIWJWLE-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-naphthalen-1-ylcarbamate Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)OC1C(CC2)CCN2C1CC1=CC=CN=C1 NUHAWKIAIWJWLE-UHFFFAOYSA-N 0.000 claims description 3
• FJJOTFOIBDTOFI-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-naphthalen-2-ylcarbamate Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)OC1C(CC2)CCN2C1CC1=CC=CN=C1 FJJOTFOIBDTOFI-UHFFFAOYSA-N 0.000 claims description 3
• PMTJTOSHJSYWNV-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-phenylcarbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC=C1 PMTJTOSHJSYWNV-UHFFFAOYSA-N 0.000 claims description 3
• VTEBTJNVEMBVJE-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-thiophen-2-ylcarbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CS1 VTEBTJNVEMBVJE-UHFFFAOYSA-N 0.000 claims description 3
• WZRLPMQPZPPFTI-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-thiophen-3-ylcarbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC=1C=CSC=1 WZRLPMQPZPPFTI-UHFFFAOYSA-N 0.000 claims description 3
• QJHVTSWUJOGVPY-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-3-carboxamide Chemical compound C=1OC2=CC=CC=C2C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 QJHVTSWUJOGVPY-UHFFFAOYSA-N 0.000 claims description 3
• KMQKKVFLNIYOLN-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzothiophene-2-carboxamide Chemical compound C=1C2=CC=CC=C2SC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 KMQKKVFLNIYOLN-UHFFFAOYSA-N 0.000 claims description 3
• CYSRBNZLJLKQPG-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzothiophene-3-carboxamide Chemical compound C=1SC2=CC=CC=C2C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 CYSRBNZLJLKQPG-UHFFFAOYSA-N 0.000 claims description 3
• XXABARHIBVIVTH-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1h-benzimidazole-2-carboxamide Chemical compound N=1C2=CC=CC=C2NC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 XXABARHIBVIVTH-UHFFFAOYSA-N 0.000 claims description 3
• RLAXVJKPOCZMTC-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indole-2-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 RLAXVJKPOCZMTC-UHFFFAOYSA-N 0.000 claims description 3
• RKKLRYOCLMHUAJ-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrole-3-carboxamide Chemical compound C1=CNC=C1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 RKKLRYOCLMHUAJ-UHFFFAOYSA-N 0.000 claims description 3
• BTDCIOANCCRNAR-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylprop-2-enamide Chemical compound C=1C=CSC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 BTDCIOANCCRNAR-UHFFFAOYSA-N 0.000 claims description 3
• MBGDQMJQLRXPPX-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylprop-2-enamide Chemical compound C1=CSC=C1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 MBGDQMJQLRXPPX-UHFFFAOYSA-N 0.000 claims description 3
• AGUPFDFSGDERMK-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 AGUPFDFSGDERMK-UHFFFAOYSA-N 0.000 claims description 3
• SFVRKZSHGMJTBE-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 SFVRKZSHGMJTBE-UHFFFAOYSA-N 0.000 claims description 3
• KROBWBZTXIWUBN-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-2-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 KROBWBZTXIWUBN-UHFFFAOYSA-N 0.000 claims description 3
• PCBNATMSIHZKCV-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 PCBNATMSIHZKCV-UHFFFAOYSA-N 0.000 claims description 3
• IDMCHCLSPBXJTC-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 IDMCHCLSPBXJTC-UHFFFAOYSA-N 0.000 claims description 3
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 3
• 208000022610 schizoaffective disease Diseases 0.000 claims description 3
• 239000011885 synergistic combination Substances 0.000 claims description 3
• ROMFFQIVCXSXDI-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound COC1=CC(OC)=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 ROMFFQIVCXSXDI-UHFFFAOYSA-N 0.000 claims description 2
• QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 claims description 2
• JKRLDMBTCOQYIN-UHFFFAOYSA-N 1-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]indole-3-carboxamide Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JKRLDMBTCOQYIN-UHFFFAOYSA-N 0.000 claims description 2
• AOWHVIJFVCTOLQ-UHFFFAOYSA-N 1-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]pyrrole-2-carboxamide Chemical compound CN1C=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 AOWHVIJFVCTOLQ-UHFFFAOYSA-N 0.000 claims description 2
• XJMWSIAJCSHRJK-UHFFFAOYSA-N 1-phenyl-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 XJMWSIAJCSHRJK-UHFFFAOYSA-N 0.000 claims description 2
• KYKZDNOHLUVSNF-UHFFFAOYSA-N 1-propan-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C(C)C)C(C(F)(F)F)=NC2=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 KYKZDNOHLUVSNF-UHFFFAOYSA-N 0.000 claims description 2
• PIMKJVXHRAXBMX-UHFFFAOYSA-N 3-(2-fluorophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound FC1=CC=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 PIMKJVXHRAXBMX-UHFFFAOYSA-N 0.000 claims description 2
• FBWUORZFZQTRGR-UHFFFAOYSA-N 3-(2-methoxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound COC1=CC=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 FBWUORZFZQTRGR-UHFFFAOYSA-N 0.000 claims description 2
• XFTSHKMQRBRWCJ-UHFFFAOYSA-N 3-(3-bromophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound BrC1=CC=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 XFTSHKMQRBRWCJ-UHFFFAOYSA-N 0.000 claims description 2
• QOFRJNKMCNOBFV-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound OC1=CC=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 QOFRJNKMCNOBFV-UHFFFAOYSA-N 0.000 claims description 2
• WSIZANVLPBEIRJ-UHFFFAOYSA-N 3-(3-methylphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound CC1=CC=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 WSIZANVLPBEIRJ-UHFFFAOYSA-N 0.000 claims description 2
• DIPCYWZEQFODFH-UHFFFAOYSA-N 3-(3-methylthiophen-2-yl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CSC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1C DIPCYWZEQFODFH-UHFFFAOYSA-N 0.000 claims description 2
• CVKGSUZQNWXLFV-UHFFFAOYSA-N 3-(4-bromophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(Br)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 CVKGSUZQNWXLFV-UHFFFAOYSA-N 0.000 claims description 2
• UTYOGONXXWCUHB-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 UTYOGONXXWCUHB-UHFFFAOYSA-N 0.000 claims description 2
• ZQCSATMPRLEZQF-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(F)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 ZQCSATMPRLEZQF-UHFFFAOYSA-N 0.000 claims description 2
• IQHVZSLMNJEPST-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 IQHVZSLMNJEPST-UHFFFAOYSA-N 0.000 claims description 2
• LCSWUZDWHFZUKB-UHFFFAOYSA-N 3-(4-propan-2-ylphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(C(C)C)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 LCSWUZDWHFZUKB-UHFFFAOYSA-N 0.000 claims description 2
• VLDYUACPWDDYFI-UHFFFAOYSA-N 3-(furan-2-yl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=COC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 VLDYUACPWDDYFI-UHFFFAOYSA-N 0.000 claims description 2
• MQNLSTVEQXKWQX-UHFFFAOYSA-N 3-ethoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1OCC MQNLSTVEQXKWQX-UHFFFAOYSA-N 0.000 claims description 2
• CMZPHAANWWYVRB-UHFFFAOYSA-N 3-methoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1OC CMZPHAANWWYVRB-UHFFFAOYSA-N 0.000 claims description 2
• FCGXEWIXCBHLJT-UHFFFAOYSA-N 3-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1C FCGXEWIXCBHLJT-UHFFFAOYSA-N 0.000 claims description 2
• AHNMFPSHBARPEN-UHFFFAOYSA-N 3-naphthalen-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 AHNMFPSHBARPEN-UHFFFAOYSA-N 0.000 claims description 2
• BHMFKHWVYBKHMM-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]but-2-enamide Chemical compound C=1C=CC=CC=1C(C)=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 BHMFKHWVYBKHMM-UHFFFAOYSA-N 0.000 claims description 2
• CVJIJXSIQBMJHS-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=CC=CC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 CVJIJXSIQBMJHS-UHFFFAOYSA-N 0.000 claims description 2
• DBHHVOXBHXZBFC-UHFFFAOYSA-N 5-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(Br)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 DBHHVOXBHXZBFC-UHFFFAOYSA-N 0.000 claims description 2
• 208000021465 Brief psychotic disease Diseases 0.000 claims description 2
• XGRDGYHIEUMRRA-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-methylphenyl)carbamate Chemical compound CC1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 XGRDGYHIEUMRRA-UHFFFAOYSA-N 0.000 claims description 2
• TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims description 2
• ISPRRZDPZDVHLE-OZYANKIXSA-N n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide;hydrochloride Chemical compound Cl.C([C@@H]1N2CCC(CC2)[C@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 ISPRRZDPZDVHLE-OZYANKIXSA-N 0.000 claims description 2
• OXKRFEWMSWPKKV-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide Chemical compound C=1C2=CC=CC=C2OC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 OXKRFEWMSWPKKV-UHFFFAOYSA-N 0.000 claims description 2
• 125000005610 enamide group Chemical group 0.000 claims 8
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 4
• CBAMUOIBMUPGKI-UHFFFAOYSA-N 1-(2-bromophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound BrC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 CBAMUOIBMUPGKI-UHFFFAOYSA-N 0.000 claims 2
• BFTUGTACCLLUEB-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound FC1=CC=CC=C1NC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 BFTUGTACCLLUEB-UHFFFAOYSA-N 0.000 claims 2
• ARGHGCDRDVRKDC-UHFFFAOYSA-N 2,4-dimethoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound COC1=CC(OC)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 ARGHGCDRDVRKDC-UHFFFAOYSA-N 0.000 claims 2
• XANDONBYNOJINR-UHFFFAOYSA-N 2-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound BrC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 XANDONBYNOJINR-UHFFFAOYSA-N 0.000 claims 2
• LHDIBSOURPEVKN-UHFFFAOYSA-N 2-chloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 LHDIBSOURPEVKN-UHFFFAOYSA-N 0.000 claims 2
• OHBLISYZWJLSAQ-UHFFFAOYSA-N 2-cyano-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC=C(C#N)C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 OHBLISYZWJLSAQ-UHFFFAOYSA-N 0.000 claims 2
• APTIKRDPDQPZIW-UHFFFAOYSA-N 2-methoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 APTIKRDPDQPZIW-UHFFFAOYSA-N 0.000 claims 2
• HWMZTJFUZBGFJP-UHFFFAOYSA-N 2-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound CC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 HWMZTJFUZBGFJP-UHFFFAOYSA-N 0.000 claims 2
• RZPIJBPBVDWNPW-UHFFFAOYSA-N 2-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound CC1=CC=CC=C1C(=S)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 RZPIJBPBVDWNPW-UHFFFAOYSA-N 0.000 claims 2
• NIVUZOANBPWSKI-UHFFFAOYSA-N 2-phenoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC=C(OC=2C=CC=CC=2)C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 NIVUZOANBPWSKI-UHFFFAOYSA-N 0.000 claims 2
• HOZJFAKGWYDDEG-UHFFFAOYSA-N 2-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HOZJFAKGWYDDEG-UHFFFAOYSA-N 0.000 claims 2
• NQVNBKFSMDSLEA-UHFFFAOYSA-N 2-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=S)NC1C(CC2)CCN2C1CC1=CC=CN=C1 NQVNBKFSMDSLEA-UHFFFAOYSA-N 0.000 claims 2
• VWRPUTHGEXQRJZ-UHFFFAOYSA-N 3,4-dichloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 VWRPUTHGEXQRJZ-UHFFFAOYSA-N 0.000 claims 2
• IPFZKDYPXYBFPN-UHFFFAOYSA-N 3-chloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 IPFZKDYPXYBFPN-UHFFFAOYSA-N 0.000 claims 2
• AGTKJIUHJASQSI-UHFFFAOYSA-N 3-cyano-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 AGTKJIUHJASQSI-UHFFFAOYSA-N 0.000 claims 2
• CSUFFYXTVYZFQF-UHFFFAOYSA-N 3-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound CC1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 CSUFFYXTVYZFQF-UHFFFAOYSA-N 0.000 claims 2
• DJVMCSAERUCIPN-UHFFFAOYSA-N 3-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound CC1=CC=CC(C(=S)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 DJVMCSAERUCIPN-UHFFFAOYSA-N 0.000 claims 2
• JHJXBUMDRXDAQN-UHFFFAOYSA-N 3-phenoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JHJXBUMDRXDAQN-UHFFFAOYSA-N 0.000 claims 2
• YKYDSKNIBFBZME-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC(C=2C=CC=CC=2)=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 YKYDSKNIBFBZME-UHFFFAOYSA-N 0.000 claims 2
• XMPNSXZCLNDEIX-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound C=1C=CC(C=2C=CC=CC=2)=CC=1C(=S)NC1C(CC2)CCN2C1CC1=CC=CN=C1 XMPNSXZCLNDEIX-UHFFFAOYSA-N 0.000 claims 2
• IJYFQAUVWBRZIV-UHFFFAOYSA-N 4-(dimethylamino)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 IJYFQAUVWBRZIV-UHFFFAOYSA-N 0.000 claims 2
• NBGNCIJGUFCCOX-UHFFFAOYSA-N 4-acetyl-3,5-dimethyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carbothioamide Chemical compound CC(=O)C1=C(C)SC(C(=S)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1C NBGNCIJGUFCCOX-UHFFFAOYSA-N 0.000 claims 2
• RPYCUDHNQUMCME-UHFFFAOYSA-N 4-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(Br)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 RPYCUDHNQUMCME-UHFFFAOYSA-N 0.000 claims 2
• GMCFDFMIXXOVSH-UHFFFAOYSA-N 4-chloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 GMCFDFMIXXOVSH-UHFFFAOYSA-N 0.000 claims 2
• HZOXZZWKNWJHDR-UHFFFAOYSA-N 4-cyano-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=C(C#N)C=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HZOXZZWKNWJHDR-UHFFFAOYSA-N 0.000 claims 2
• IKXYPVOSZVQOPI-UHFFFAOYSA-N 4-methoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 IKXYPVOSZVQOPI-UHFFFAOYSA-N 0.000 claims 2
• SGSBBSYITGHTSX-UHFFFAOYSA-N 4-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 SGSBBSYITGHTSX-UHFFFAOYSA-N 0.000 claims 2
• WYMNJVRGIMDBDE-UHFFFAOYSA-N 4-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound C1=CC(C)=CC=C1C(=S)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 WYMNJVRGIMDBDE-UHFFFAOYSA-N 0.000 claims 2
• QUUZVLSBZNXIKV-UHFFFAOYSA-N 4-phenoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 QUUZVLSBZNXIKV-UHFFFAOYSA-N 0.000 claims 2
• QIIDAZYTEGIRPF-UHFFFAOYSA-N 4-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 QIIDAZYTEGIRPF-UHFFFAOYSA-N 0.000 claims 2
• JSTXIWYWUOOPIZ-UHFFFAOYSA-N 4-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=S)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JSTXIWYWUOOPIZ-UHFFFAOYSA-N 0.000 claims 2
• RAIBXAZQPIYPQN-UHFFFAOYSA-N 5-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]pyridine-3-carboxamide Chemical compound C=1N=CC(C=2C=CC=CC=2)=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 RAIBXAZQPIYPQN-UHFFFAOYSA-N 0.000 claims 2
• CJNZWFIMFCTJLU-UHFFFAOYSA-N 6-chloro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]pyridine-3-carboxamide Chemical compound C1=NC(Cl)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 CJNZWFIMFCTJLU-UHFFFAOYSA-N 0.000 claims 2
• WZCSDVIZDJOJJL-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-chlorophenyl)carbamate Chemical compound C1=CC(Cl)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 WZCSDVIZDJOJJL-UHFFFAOYSA-N 0.000 claims 2
• YWHAUAVPYNZOSF-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indole-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 YWHAUAVPYNZOSF-UHFFFAOYSA-N 0.000 claims 2
• UTUHXCMDJIEYQJ-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 UTUHXCMDJIEYQJ-UHFFFAOYSA-N 0.000 claims 2
• MIDMQKCTNPHIDM-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 MIDMQKCTNPHIDM-UHFFFAOYSA-N 0.000 claims 2
• VBLUZKSBGJHSIJ-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]furan-3-carboxamide Chemical compound C1=COC=C1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 VBLUZKSBGJHSIJ-UHFFFAOYSA-N 0.000 claims 2
• SBDOSRWGEWIYEP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2OC(C(=O)N)=CC2=C1 SBDOSRWGEWIYEP-UHFFFAOYSA-N 0.000 claims 1
• JHNPAFQVHHLCLU-UHFFFAOYSA-N 3-(3-fluorophenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound FC1=CC=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 JHNPAFQVHHLCLU-UHFFFAOYSA-N 0.000 claims 1
• SJERZLUHIKDTOI-UHFFFAOYSA-N 3-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound BrC1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 SJERZLUHIKDTOI-UHFFFAOYSA-N 0.000 claims 1
• LBAWCAVCFYWKTG-UHFFFAOYSA-N 3-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1Br LBAWCAVCFYWKTG-UHFFFAOYSA-N 0.000 claims 1
• INYKXHJLJAWSKB-UHFFFAOYSA-N 3-methoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound COC1=CC=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 INYKXHJLJAWSKB-UHFFFAOYSA-N 0.000 claims 1
• BORJMDSGJMHFPM-UHFFFAOYSA-N 3-pyridin-3-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 BORJMDSGJMHFPM-UHFFFAOYSA-N 0.000 claims 1
• KFRKYSXFQWSQSR-UHFFFAOYSA-N 5-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]pyridine-3-carboxamide Chemical compound BrC1=CN=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 KFRKYSXFQWSQSR-UHFFFAOYSA-N 0.000 claims 1
• APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 claims 1
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 181
• 241000699670 Mus sp. Species 0.000 description 130
• 229960003638 dopamine Drugs 0.000 description 90
• 210000004556 brain Anatomy 0.000 description 81
• 230000000694 effects Effects 0.000 description 75
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 62
• 238000012360 testing method Methods 0.000 description 57
• 230000006977 prepulse inhibition Effects 0.000 description 54
• 229940126062 Compound A Drugs 0.000 description 52
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 52
• 210000002569 neuron Anatomy 0.000 description 52
• 241000700159 Rattus Species 0.000 description 48
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 45
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 45
• 238000000034 method Methods 0.000 description 35
• 210000004515 ventral tegmental area Anatomy 0.000 description 35
• 239000000203 mixture Substances 0.000 description 34
• 208000024891 symptom Diseases 0.000 description 34
• 229940079593 drug Drugs 0.000 description 32
• 241001465754 Metazoa Species 0.000 description 31
• 230000001537 neural effect Effects 0.000 description 30
• 102000005962 receptors Human genes 0.000 description 29
• 108020003175 receptors Proteins 0.000 description 29
• 239000000835 fiber Substances 0.000 description 27
• 229940124597 therapeutic agent Drugs 0.000 description 25
• 229960002715 nicotine Drugs 0.000 description 24
• 210000004940 nucleus Anatomy 0.000 description 24
• 210000003523 substantia nigra Anatomy 0.000 description 24
• 241000699660 Mus musculus Species 0.000 description 23
• 238000011830 transgenic mouse model Methods 0.000 description 23
• 210000004027 cell Anatomy 0.000 description 22
• 230000024188 startle response Effects 0.000 description 22
• 206010012601 diabetes mellitus Diseases 0.000 description 21
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 21
• DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 20
• 230000027455 binding Effects 0.000 description 19
• 208000035475 disorder Diseases 0.000 description 19
• 230000009151 sensory gating Effects 0.000 description 19
• 230000000862 serotonergic effect Effects 0.000 description 19
• 239000000556 agonist Substances 0.000 description 18
• 230000006399 behavior Effects 0.000 description 18
• 238000011161 development Methods 0.000 description 18
• 230000018109 developmental process Effects 0.000 description 18
• 230000001965 increasing effect Effects 0.000 description 18
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 17
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 17
• 230000009261 transgenic effect Effects 0.000 description 17
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 16
• 239000003981 vehicle Substances 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 208000021017 Weight Gain Diseases 0.000 description 15
• 230000004913 activation Effects 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 15
• 235000019786 weight gain Nutrition 0.000 description 15
• HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 14
• 230000001054 cortical effect Effects 0.000 description 14
• 210000001259 mesencephalon Anatomy 0.000 description 14
• 230000000698 schizophrenic effect Effects 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 230000004584 weight gain Effects 0.000 description 14
• 235000013305 food Nutrition 0.000 description 13
• 230000007246 mechanism Effects 0.000 description 13
• 230000004044 response Effects 0.000 description 13
• 230000011664 signaling Effects 0.000 description 13
• 201000010099 disease Diseases 0.000 description 12
• 230000001771 impaired effect Effects 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 210000001577 neostriatum Anatomy 0.000 description 12
• 230000011273 social behavior Effects 0.000 description 12
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 230000000971 hippocampal effect Effects 0.000 description 11
• 230000008765 hyperinnervation Effects 0.000 description 11
• 230000003993 interaction Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 230000036278 prepulse Effects 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 229940076279 serotonin Drugs 0.000 description 11
• 235000000346 sugar Nutrition 0.000 description 11
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 10
• 238000000540 analysis of variance Methods 0.000 description 10
• 238000010171 animal model Methods 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 230000003542 behavioural effect Effects 0.000 description 9
• 230000007278 cognition impairment Effects 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 238000011835 investigation Methods 0.000 description 9
• 230000015654 memory Effects 0.000 description 9
• 210000002442 prefrontal cortex Anatomy 0.000 description 9
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 8
• RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 8
• 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 8
• 210000003169 central nervous system Anatomy 0.000 description 8
• 230000002950 deficient Effects 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 230000002739 subcortical effect Effects 0.000 description 8
• 230000003936 working memory Effects 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 7
• 108091008794 FGF receptors Proteins 0.000 description 7
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 210000005153 frontal cortex Anatomy 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 239000003176 neuroleptic agent Substances 0.000 description 7
• 230000000701 neuroleptic effect Effects 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 208000032928 Dyslipidaemia Diseases 0.000 description 6
• 208000004547 Hallucinations Diseases 0.000 description 6
• 208000017170 Lipid metabolism disease Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 238000000692 Student's t-test Methods 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 239000002858 neurotransmitter agent Substances 0.000 description 6
• 210000001009 nucleus accumben Anatomy 0.000 description 6
• 210000002381 plasma Anatomy 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 206010011953 Decreased activity Diseases 0.000 description 5
• 206010012239 Delusion Diseases 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 5
• 240000007472 Leucaena leucocephala Species 0.000 description 5
• 206010041243 Social avoidant behaviour Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 208000010877 cognitive disease Diseases 0.000 description 5
• 210000003618 cortical neuron Anatomy 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 231100000868 delusion Toxicity 0.000 description 5
• 230000003292 diminished effect Effects 0.000 description 5
• 210000005064 dopaminergic neuron Anatomy 0.000 description 5
• 230000009977 dual effect Effects 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 210000001320 hippocampus Anatomy 0.000 description 5
• 208000013403 hyperactivity Diseases 0.000 description 5
• 230000001096 hypoplastic effect Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 230000013016 learning Effects 0.000 description 5
• 238000012346 open field test Methods 0.000 description 5
• 238000004445 quantitative analysis Methods 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000000391 smoking effect Effects 0.000 description 5
• 230000003997 social interaction Effects 0.000 description 5
• 238000012353 t test Methods 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• TYAGAVRSOFABFO-VIFPVBQESA-N (5s)-spiro[1,3-oxazolidine-5,3'-1-azabicyclo[2.2.2]octane]-2-one Chemical compound O1C(=O)NC[C@]11C(CC2)CCN2C1 TYAGAVRSOFABFO-VIFPVBQESA-N 0.000 description 4
• CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 4
• 102000035037 5-HT3 receptors Human genes 0.000 description 4
• 108091005477 5-HT3 receptors Proteins 0.000 description 4
• 108010077544 Chromatin Proteins 0.000 description 4
• 208000028698 Cognitive impairment Diseases 0.000 description 4
• 101150104779 HTR2A gene Proteins 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 4
• 229940123925 Nicotinic receptor agonist Drugs 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 229920005372 Plexiglas® Polymers 0.000 description 4
• 206010046996 Varicose vein Diseases 0.000 description 4
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
• 229960004373 acetylcholine Drugs 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 230000005540 biological transmission Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 244000309464 bull Species 0.000 description 4
• 210000003483 chromatin Anatomy 0.000 description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
• 230000003291 dopaminomimetic effect Effects 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 4
• 210000004295 hippocampal neuron Anatomy 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• HSEQUIRZHDYOIX-ZOWNYOTGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 HSEQUIRZHDYOIX-ZOWNYOTGSA-N 0.000 description 4
• 230000001123 neurodevelopmental effect Effects 0.000 description 4
• 238000001543 one-way ANOVA Methods 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 125000003367 polycyclic group Chemical group 0.000 description 4
• 239000004926 polymethyl methacrylate Substances 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 230000003518 presynaptic effect Effects 0.000 description 4
• 210000001609 raphe nuclei Anatomy 0.000 description 4
• 229940044601 receptor agonist Drugs 0.000 description 4
• 239000000018 receptor agonist Substances 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000012549 training Methods 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• 238000011765 DBA/2 mouse Methods 0.000 description 3
• 208000027776 Extrapyramidal disease Diseases 0.000 description 3
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
• 208000003098 Ganglion Cysts Diseases 0.000 description 3
• 102100031775 Leptin receptor Human genes 0.000 description 3
• 101100522284 Orgyia pseudotsugata multicapsid polyhedrosis virus PTP-1 gene Proteins 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 102000009572 RNA Polymerase II Human genes 0.000 description 3
• 108010009460 RNA Polymerase II Proteins 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 229910000831 Steel Inorganic materials 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 208000005400 Synovial Cyst Diseases 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 229940025084 amphetamine Drugs 0.000 description 3
• 210000004727 amygdala Anatomy 0.000 description 3
• 239000007900 aqueous suspension Substances 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 210000005013 brain tissue Anatomy 0.000 description 3
• 150000003943 catecholamines Chemical class 0.000 description 3
• 230000001713 cholinergic effect Effects 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 230000019771 cognition Effects 0.000 description 3
• 239000012050 conventional carrier Substances 0.000 description 3
• 230000004424 eye movement Effects 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003016 hypothalamus Anatomy 0.000 description 3
• 238000005286 illumination Methods 0.000 description 3
• 238000003365 immunocytochemistry Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 108010019813 leptin receptors Proteins 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000003988 neural development Effects 0.000 description 3
• 230000001722 neurochemical effect Effects 0.000 description 3
• 230000004112 neuroprotection Effects 0.000 description 3
• 235000014571 nuts Nutrition 0.000 description 3
• 210000000287 oocyte Anatomy 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000004031 partial agonist Substances 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002360 prefrontal effect Effects 0.000 description 3
• QJWFJOSRSZOLKK-UHFFFAOYSA-N prop-2-enamide Chemical compound NC(=O)C=C.NC(=O)C=C QJWFJOSRSZOLKK-UHFFFAOYSA-N 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 125000004076 pyridyl group Chemical group 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 230000031893 sensory processing Effects 0.000 description 3
• 238000002603 single-photon emission computed tomography Methods 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 239000010959 steel Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 230000000946 synaptic effect Effects 0.000 description 3
• 230000005062 synaptic transmission Effects 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 229940116362 tragacanth Drugs 0.000 description 3
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 description 2
• DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
• 108020005029 5' Flanking Region Proteins 0.000 description 2
• 210000002348 5-ht neuron Anatomy 0.000 description 2
• PIEZNFVNSICXLK-FUHWJXTLSA-N 5-methyl-n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N[C@H]1[C@H](CC=2C=NC=CC=2)N2CCC1CC2 PIEZNFVNSICXLK-FUHWJXTLSA-N 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• AUBPMADJYNSPOA-UHFFFAOYSA-N Anabaseine Chemical compound C1CCCC(C=2C=NC=CC=2)=N1 AUBPMADJYNSPOA-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 241001573498 Compacta Species 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 206010052804 Drug tolerance Diseases 0.000 description 2
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
• 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• XLTANAWLDBYGFU-LSVDIXQKSA-N [3h]-mla Chemical compound C([C@]12[C@H]3[C@H](OC)[C@]4([C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@]3([C@@H]4N(CC)C2)[C@@H](OC)CC1)O)OC(=O)C=1C([3H])=CC=CC=1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-LSVDIXQKSA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 2
• 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
• 229960003805 amantadine Drugs 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 229940124604 anti-psychotic medication Drugs 0.000 description 2
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
• 229960004046 apomorphine Drugs 0.000 description 2
• CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 230000006736 behavioral deficit Effects 0.000 description 2
• 208000013404 behavioral symptom Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000004641 brain development Effects 0.000 description 2
• 230000003925 brain function Effects 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• 238000009395 breeding Methods 0.000 description 2
• 230000001488 breeding effect Effects 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000003185 calcium uptake Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000007248 cellular mechanism Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 229960003920 cocaine Drugs 0.000 description 2
• 239000003240 coconut oil Substances 0.000 description 2
• 235000019864 coconut oil Nutrition 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 230000003920 cognitive function Effects 0.000 description 2
• 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000003255 drug test Methods 0.000 description 2
• 239000008157 edible vegetable oil Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000007608 epigenetic mechanism Effects 0.000 description 2
• 230000002964 excitative effect Effects 0.000 description 2
• 230000000193 eyeblink Effects 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 235000012631 food intake Nutrition 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 230000003371 gabaergic effect Effects 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 230000009395 genetic defect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 230000026781 habituation Effects 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 210000001153 interneuron Anatomy 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 210000004731 jugular vein Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000002197 limbic effect Effects 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 230000027928 long-term synaptic potentiation Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
• 229960003105 metformin Drugs 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• XLTANAWLDBYGFU-VTLKBQQISA-N methyllycaconitine Chemical compound C([C@]12CN([C@@H]3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-VTLKBQQISA-N 0.000 description 2
• 230000037023 motor activity Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 229920001206 natural gum Polymers 0.000 description 2
• 230000000508 neurotrophic effect Effects 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 238000011458 pharmacological treatment Methods 0.000 description 2
• 238000001050 pharmacotherapy Methods 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229940126027 positive allosteric modulator Drugs 0.000 description 2
• 238000010149 post-hoc-test Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
• 239000002287 radioligand Substances 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000004434 saccadic eye movement Effects 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 230000036306 sensory inhibition Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000002400 serotonin 2A antagonist Substances 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
• 229960004425 sibutramine Drugs 0.000 description 2
• 230000004039 social cognition Effects 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• 229960004394 topiramate Drugs 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000003363 transsynaptic effect Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
• STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
• RASGVORPWAYILQ-UHFFFAOYSA-N 1-azabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCC2 RASGVORPWAYILQ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• 108700020469 14-3-3 Proteins 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
• LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
• KFPTXAUKYBTSEX-UHFFFAOYSA-N 2-methyl-3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2NC(=O)C(C)=CC1=CC=CC=C1 KFPTXAUKYBTSEX-UHFFFAOYSA-N 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• BXESJQBDGAEMNV-UHFFFAOYSA-N 3-(3-methoxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound COC1=CC=CC(C=CC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 BXESJQBDGAEMNV-UHFFFAOYSA-N 0.000 description 1
• YVCCTXSCQDPZQH-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(O)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 YVCCTXSCQDPZQH-UHFFFAOYSA-N 0.000 description 1
• RQQUKWIMHNKCNE-UHFFFAOYSA-N 3-(4-methylphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 RQQUKWIMHNKCNE-UHFFFAOYSA-N 0.000 description 1
• BXKYFUGAAFLYJL-BXGYHSFXSA-N 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 BXKYFUGAAFLYJL-BXGYHSFXSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 230000007730 Akt signaling Effects 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000007415 Anhedonia Diseases 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 208000036640 Asperger disease Diseases 0.000 description 1
• 201000006062 Asperger syndrome Diseases 0.000 description 1
• 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 description 1
• 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
• 241001598984 Bromius obscurus Species 0.000 description 1
• 102000001764 CREB-Binding Protein Human genes 0.000 description 1
• 108010040163 CREB-Binding Protein Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000754798 Calophyllum brasiliense Species 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010051290 Central nervous system lesion Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000009660 Cholinergic Receptors Human genes 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 101150049660 DRD2 gene Proteins 0.000 description 1
• 206010054089 Depressive symptom Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 102100022273 Disrupted in schizophrenia 1 protein Human genes 0.000 description 1
• 102220485376 Disrupted in schizophrenia 1 protein_S704C_mutation Human genes 0.000 description 1
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
• 108050004812 Dopamine receptor Proteins 0.000 description 1
• 102000015554 Dopamine receptor Human genes 0.000 description 1
• 101100066896 Drosophila melanogaster cher gene Proteins 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 240000008672 Gynura procumbens Species 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000902072 Homo sapiens Disrupted in schizophrenia 1 protein Proteins 0.000 description 1
• 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
• 101000822103 Homo sapiens Neuronal acetylcholine receptor subunit alpha-7 Proteins 0.000 description 1
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 238000012313 Kruskal-Wallis test Methods 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 238000012347 Morris Water Maze Methods 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• 102100021511 Neuronal acetylcholine receptor subunit alpha-7 Human genes 0.000 description 1
• 229940123565 Neuronal nicotinic receptor agonist Drugs 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
• 206010036467 Poverty of speech Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
• 235000011449 Rosa Nutrition 0.000 description 1
• 206010039424 Salivary hypersecretion Diseases 0.000 description 1
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
• 208000008630 Sialorrhea Diseases 0.000 description 1
• 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
• 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
• 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 101150076211 TH gene Proteins 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 241000244040 Terranova Species 0.000 description 1
• GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
• 241000387514 Waldo Species 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• ZZOPUMOBMOFBGN-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(2,4-dimethoxyphenyl)carbamate Chemical compound COC1=CC(OC)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 ZZOPUMOBMOFBGN-UHFFFAOYSA-N 0.000 description 1
• RZTPSIBVICLTBT-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-[3-(trifluoromethyl)phenyl]carbamate Chemical compound FC(F)(F)C1=CC=CC(NC(=O)OC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 RZTPSIBVICLTBT-UHFFFAOYSA-N 0.000 description 1
• XQNNVUIPMSMJBO-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-[4-(dimethylamino)phenyl]carbamate Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 XQNNVUIPMSMJBO-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 229940125516 allosteric modulator Drugs 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000000454 anti-cipatory effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• 208000029560 autism spectrum disease Diseases 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000002779 brain fornix Anatomy 0.000 description 1
• 230000011496 cAMP-mediated signaling Effects 0.000 description 1
• 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000023715 cellular developmental process Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000003576 central nervous system agent Substances 0.000 description 1
• 229940125693 central nervous system agent Drugs 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000037411 cognitive enhancing Effects 0.000 description 1
• 230000003931 cognitive performance Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000001739 density measurement Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
• 230000010249 dopaminergic function Effects 0.000 description 1
• 210000001029 dorsal striatum Anatomy 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 238000000835 electrochemical detection Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 230000001073 episodic memory Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000002461 excitatory amino acid Effects 0.000 description 1
• 239000003257 excitatory amino acid Substances 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000021824 exploration behavior Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 230000000494 facilitatory effect Effects 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 239000012054 flavored emulsion Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 238000007667 floating Methods 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• GOLHZPOXCLTFRB-UHFFFAOYSA-N furan-3-carboxamide Chemical compound NC(=O)C=1C=COC=1 GOLHZPOXCLTFRB-UHFFFAOYSA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
• 230000000574 ganglionic effect Effects 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 230000007946 glucose deprivation Effects 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 210000001362 glutamatergic neuron Anatomy 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000006195 histone acetylation Effects 0.000 description 1
• QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000012151 immunohistochemical method Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• CANPFCFJURGKAX-JTQLQIEISA-N iolopride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(I)=CC=C1OC CANPFCFJURGKAX-JTQLQIEISA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229910052743 krypton Inorganic materials 0.000 description 1
• DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000006386 memory function Effects 0.000 description 1
• 230000007334 memory performance Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• GUUAJKBOCMZUJW-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=CC2=C1OC(C(=O)N[C@@H]1C3CCN(CC3)C1)=C2 GUUAJKBOCMZUJW-IBGZPJMESA-N 0.000 description 1
• PTGWFYYEAUFEAS-ZYHUDNBSSA-N n-[(3r,5r)-1-azabicyclo[3.2.1]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1CN2CC[C@@](C2)(C1)[H])C(=O)C(N=C1)=CC2=C1OC=C2 PTGWFYYEAUFEAS-ZYHUDNBSSA-N 0.000 description 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 229940105631 nembutal Drugs 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 230000003957 neurotransmitter release Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 108020004017 nuclear receptors Proteins 0.000 description 1
• 238000013116 obese mouse model Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
• 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000011505 plaster Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000004800 psychological effect Effects 0.000 description 1
• 239000003368 psychostimulant agent Substances 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000004080 punching Methods 0.000 description 1
• 238000004451 qualitative analysis Methods 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 150000008584 quinuclidines Chemical class 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 101150110872 ric-3 gene Proteins 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• SIIICDNNMDMWCI-YJNKXOJESA-N rti-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229940124711 schizophrenia therapeutics Drugs 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 238000007391 self-medication Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000020374 simple syrup Nutrition 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 230000006886 spatial memory Effects 0.000 description 1
• RXLOZRCLQMJJLC-UHFFFAOYSA-N ssr-180,711 Chemical compound C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 RXLOZRCLQMJJLC-UHFFFAOYSA-N 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000010245 stereological analysis Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000010907 stover Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000007428 synaptic transmission, GABAergic Effects 0.000 description 1
• 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
• 230000009044 synergistic interaction Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 210000001587 telencephalon Anatomy 0.000 description 1
• 230000000542 thalamic effect Effects 0.000 description 1
• 230000003461 thalamocortical effect Effects 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000001391 thioamide group Chemical group 0.000 description 1
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000005111 ventral hippocampus Anatomy 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1